The Government is now operating in accordance with the Caretaker Conventions pending the outcome of the 2022 federal election.

COVID-19 vaccine doses and administration

There are 4 COVID-19 vaccines approved for use in Australia. Find out their dosage, volume and schedules.

Comirnaty – generic name Tozinameran or BNT162b2

Category

Detail

Sponsor

Pfizer Australia Pty Ltd

Approved age for use

≥12 years

Presentation

Multidose vial without preservative. Each vial containing 6 doses in 0.45mL. Requires dilution with 1.8 mL of sterile 0.9% NaCl without preservative into each multidose vial

Cap colour Purple

Volume/strength

0.3 mL (30 µg) per dose

Schedule

2 dose, 3-8 weeks apart apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.3 mL dose contains 30 µg mRNA encoding the SARS-CoV-2 spike glycoprotein

Excipients

  • ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
  • 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
  • distearoylphosphatidylcholine (DSPC)
  • cholesterol
  • potassium chloride
  • monobasic potassium phosphate
  • sodium chloride
  • dibasic sodium phosphate dihydrate
  • sucrose
  • water for injection

Paediatric Comirnaty (5 – 11 formulation) – generic name Tozinameran or BNT162b2

Category

Detail

Sponsor

Pfizer Australia Pty Ltd

Approved age for use

5 to <12 years

Presentation

Tris/Sucrose presentation. Multidose vial containing 10 doses in 1.3mL. Requires dilution with 1.3 mL of sterile 0.9% NaCl without preservative into each multidose viall

Cap colour Orange

Volume/strength

0.2 mL (10 µg) per dose

Schedule

2 doses, 8 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.2 mL dose contains 10 µg mRNA encoding the SARS-CoV-2 spike glycoprotein

Excipients

  • ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
  • 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
  • distearoylphosphatidylcholine (DSPC)
  • cholesterol
  • trometamol
  • trometamol hydrochloride
  • sucrose
  • water for injection

Spikevax (Moderna) – generic name Elasomeran or mRNA-1273

Category

Detail

Sponsor

Moderna Australia Pty Ltd

Approved age for use

≥6 years

Presentation

Multidose vial without preservative, each vial containing 10 full doses in 5 mL

Volume/strength

For children aged 6 to 11 years: 0.25 mL per dose

For people aged ≥12 years as a primary course: 0.5 mL per dose

For people aged ≥18 years as a booster: 0.25 mL per dose

Schedule

For children aged 6 to 11 years: 2 doses, 8 weeks apart

For people aged ≥12 years: 2 doses, 4-8 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.5 mL dose contains 100 μg mRNA encoding the SARS-CoV-2 spike glycoprotein (50 ug in each 0.25 mL dose)

Excipients

  • heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate
  • cholesterol
  • distearoylphosphatidylcholine
  • 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
  • trometamol
  • trometamol hydrochloride
  • acetic acid
  • sodium acetate trihydrate
  • sucrose
  • water for injection

Vaxzevria (AstraZeneca) – generic name ChAdOx1s

Category

Detail

Sponsor

AstraZeneca Pty Ltd

Approved age for use

≥18 years

Presentation

Multidose vial without preservative, each vial containing either 8 doses in 4 mL or 10 doses in 5 mL

Volume/strength

0.5 mL per dose

Schedule

2 doses, 4 to 12 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.5 mL dose contains 5 x 1010 viral particles of ChAdOx1-S, a recombinant, non-replicating chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein

Excipients

  • histidine
  • histidine hydrochloride monohydrate
  • sodium chloride
  • magnesium chloride hexahydrate
  • disodium edetate (EDTA)
  • sucrose
  • ethanol absolute
  • polysorbate 80
  • water for injection

Nuvaxovid (Novavax)– generic name NVX-CoV2373

Category

Detail

Sponsor

Biocelect Pty Ltd on behalf of Novavax Ltd

Approved age for use

≥18 years

Presentation

Multidose vial without preservative, each vial containing 10 doses in 5 mL

Volume/strength

5 µg antigen, 50 µg Matrix-M

Schedule

2 doses, 3-8 weeks apart

Administration route

Intramuscular injection into deltoid muscle

Ingredients

Each 0.5 mL dose contains 5 µg of SARS-CoV-2 spike protein, adjuvanted with Matrix-M.

Adjuvant Matrix-M contains Fraction-A (42.5 µg) and Fraction-C (7.5 µg) of Quillaja saponaria Molina extract

Excipients

  • Dibasic sodium phosphate heptahydrate
  • Monobasic sodium phosphate monohydrate
  • Sodium chloride
  • Polysorbate 80
  • Sodium hydroxide (for adjustment of pH)
  • Hydrochloric acid (for adjustment of pH)
  • Water for Injections
  • Adjuvant (Matrix M)
    • Quillaja saponaria saponins fraction A
    • Quillaja saponaria saponins fraction C
    • Cholesterol
    • Phosphatidyl choline
    • Monobasic potassium phosphate
    • Potassium chloride
Last updated: 
2 May 2022

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.